The study was based upon preclinical data suggesting that this combination may offer the chance to overcome trastuzumab resistance [13]; safety and efficacy of trastuzumab plus pembrolizumab in HER2-positive metastatic breast cancer patients with PD-L1 expressing tumours was defined as the primary study endpoint. This evidence concerns the gene ERBB2 and neoplasm.